Spread of carbapenemase producers in
Although rarely reported a decade ago, carbapenemase-producers in Enterobacteriaceae, they are extensively reported nowadays. Different groups of enzymes possessing carbapenemase properties have emerged, and are spreading worldwide concomitantly. Some of those enzymes hydrolyze carbapenems very efficiently whereas others exhibit weak activity against carbapenems. Some include broad-spectrum cephalosporins in their hydrolytic pattern, some do not. Some have an activity that may be inhibited (at least partially) by ß-lactamase inhibitors (such as clavulanic acid, tazobactam) whereas most are not inhibited by clinicallyavailable inhibitors. However, those significant differences do not really explain the success of the spread of specific enzymes in specific countries or areas [1] .
The main features related to the epidemiology of those enzymes are as follows; p i) The first parameter is the primary reservoir. Indeed it is very likely that a specific enzyme emerges in a given geographical area where many favorable conditions exist such as highdensity population, poor hygiene, high selective pressure linked to over-and misuse of antibiotics.
ii) The second parameter corresponds to the genetics of the carbapenemase gene, since some genetic structures are prone to enhance gene plasticity and mobility. Some integron or transposon structures and plasmids may indeed favorize horizontal gene transfer. Some plasmids possess broad-host range of replication, and can therefore enhance the inter-species dissemination, while some others possess narrow-host range. Some plasmids replicate very efficiently and are self-conjugative, while others are not self-conjugative or conjugate at very low rate. The genetic background of the strain harbouring the carbapenemase gene may also play an important role, since the emergence of one gene in a so-called successful clone (being for instances more prompt to disseminate from patient to patient, or more prompt to resist on dry surfaces) can favorize the initial spread of a carbapenemase through the spread of the corresponding bacterial host. The first variant of the GES family (for "Guiana Extended-Spectrum ß-lactamase") which is GES-1 which is not a carbapenemase was reported in 2000. The GES family now includes 24 variants (http://www.lahey.org/Studies/other.asp#table1) [15] . All the GES variants possess the ability to hydrolyze broad-spectrum cephalosporins, but through specific amino acid substitutions inside the active site, the extension of their spectrum of activity towards carbapenems has been identified for several variants [16] . Among these variants, the GES-2, -4, -5, -6, -11, -14, and -18 hydrolyze imipenem efficiently [17] . Although quite rare, GES enzymes have been identified worldwide. Among those GES variants for which a significant carbapenemase activity is noticed, there are; GES-2 identified in Pseudomonas aeruginosa, with one clone being the source of a nosocomial outbreak in South Africa [18] ; p GES-5 identified in Enterobacteriaceae and P. aeruginosa, being widely reported in South America (Brazil) [19, 20] Recently, the KHM-1 ß-lactamase has been identified in Japan from a single C. freundii clinical isolate that had been recovered in 1997 [39] . The GIM-1 MBL (that stands for "German Imipenemase") which has been firstly identified from a P. aeruginosa isolate from Germany [38] has been then identified in other P. aeruginosa isolates [53] but also in Serratia marcescens [54] , Enterobacter cloacae [55] and Acinetobacter pittii [56] . Worringly, it was recently shown that GIM-1 was identified in many enterobacterial species, including E. One of the most most clinically-significant carbapenemase is NDM-1 (New Delhi metallo-β-lactamase) described in 2009, the corresponding K. pneumoniae and E. coli isolates being from a Swedish patient of Indian origin hospitalized in Örebro, Sweden, after a hospital stay in New Delhi [62, 63] . NDM-1 shares very little identity with other MBLs, the most similar being VIM-1/VIM-2 with only 32.4% amino acid identity. NDM-1 efficiently hydrolyses a broad range of β-lactams including penicillins, cephalosporins and carbapenems, just sparing monobactams such as aztreonam [62] . Since the first description of NDM-1, eight variants of this enzyme have been published (NDM-1 to -8) and twelve have been assigned (http://www.lahey.org), most of them originated from Asia [64] [65] [66] . Compared to NDM-1, the NDM-4, NDM-5 and NDM-7 variants possess increased activity towards carbapenems [67] [68] [69] [70] . A detailed analysis of the resistance patterns show their systematic association with other antibiotic resistance determinants such as plasmid-mediated AmpC cephalosporinases, p clavulanic-acid inhibited expanded-spectrum ß-lactamases (ESBLs), other types of carbapenemases (OXA-48-, VIM-, KPC-types), broad spectrum resistance to aminoglycosides (16S RNA methylases), to quinolones (Qnr), to macrolides (esterases), to rifampicin (rifampicin-modifying enzymes), to chloramphenicol and to sulfamethoxazole [71, 72] . Consequently, many of the NDM-1 producers remain susceptible only to colistin, fosfomycin and tigecycline [73] .
The main identified reservoir of NDM-producing Enterobacteriaceae is the Indian subcontinent (Pakistan, India, Sri Lanka) [63] . Spread of NDM producers has been not only extensively identified among patients from the Indian subcontinent but also from the soil [74, 75] . Therefore, it is likely that there the environment is already heavily contaminated by NDM producers. The prevalence of carriage is estimated at 5 to 15 % in that part of the world [76, 77] . A significant spread of NDM producers has been identified also in the Great Britain with tight relationships with India and Pakistan [65] . Subsequently, NDM producers in
Enterobacteriaceae have been reported almost worldwide including many countries in Asia, Africa, Australia, America, and Europe [78] . NDM producers are now on the top list of carbapenemase producers in European countries such as in the UK and in France [63, 65] . All types of NDM-producing enterobacterial species have been found involved in infections, but mostly K. pneumoniae and E. coli are sources of hospital and community acquired infections, respectively. The frequent identification of NDM-producing E. coli is of concern considering that E. coli is the first pathogen responsible for urinary tract infections, community-acquired infections, and diarrhea [88] . In fact, antibiotic resistance occurring in community settings are by definition very difficult to be contained and diarrhea is the source of a further spread of NDM producers in the environment at least in South East Asia.
p
It may therefore be expected that outbreaks due mostly to NDM-producing K.
pneumoniae will be increasingly reported worldwide and concomitantly, a slow but progressive increase in the prevalence rate of NDM-producing E. coli will be observed, mirrorring the spread of CTX-M producers we have observed in community setttings since the 2000's. Noteworthy, outbreaks with NDM-1-producing E. coli or E. cloacae have been reported in Bulgaria and Turkey, respectively [89, 90] . It is however difficult to evaluate the time (years) it will take to obtain similar prevalence rates of NDM-producing E. coli comparable to those observed for CTX-M producers (15-70% depending of the countries).
Long-term persistence of NDM producers in the human gut will contribute to further humanto-human transfer [91] , leading to some autochthonous cases in non endemic area as observed in France [92] .
The carbapenem-hydrolysing class D ß-lactamases
Class D ß-lactamases, also named OXAs (for "oxacillinases") include now more than 400 enzymes, among which only some variants actually possess a carbapenemase activity [93] . by a single amino acid substitution together with a four amino-acid deletion [95, 136] .
Interestingly, although its carbapenemase activity is lower than that of OXA-48, its substrate profile includes broad-spectrum cephalosporins and its activity is partially inhibited by clavulanic acid, thus conferring to the corresponding enterobacterial recipient strains an resistance phenotype very similar to that of an ESBL producer. OXA-163 was originally identified from enterobacterial isolates (E. cloacae and K. pneumoniae) recovered in Argentina [136] , and then in Egypt [137] . Other studies confirmed that OXA-163 producers were frequently identified in Argentina [30] , and one single amino acid mutant (OXA-247)
sharing the same hydrolytic properties was identified in that country [138] . 
